Protai empowers drug discovery with Proteomics and ML to unlock new layers of biological insights to combat complex diseases. Protai’s Artificial Intelligence platform has made a leap in solving how drug candidates are created and validated, facilitating quicker and more advanced drug discovery. Protai is backed by mission-driven leading VC funds Grove Ventures and Pitango HealthTech. The founders, Eran Seger and Kirill Pevzner, are experienced entrepreneurs and tech executives, alumni of Israeli intelligence cyber corps, and are supported by renowned scientific experts.